Is the CSL share price heading back over $300 in 2022?

Is 2022 CSL's year of $300 a share?

| More on:
A doctor looks unsure, indicating share price uncertainty for ASX medical companies

Image source: Getty images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has been stuck on struggle street for a while now
  • The company has been treading water for some years and hasn't seen $300 a share so far in 2022
  • But could this be the year where CSL shares resume their growth?

The CSL Limited (ASX: CSL) share price has been somewhat of a lacklustre performer of late, especially when compared to its stellar runs of a few years ago. At the time of writing, CSL shares are going for $269.12 each, up a healthy 2.03% so far today.

However, CSL first crossed this pricing threshold back in November 2019. That means this ASX 200 healthcare giant has essentially been treading water ever since. That's 2-and-a-half years of waiting that shareholders have had to endure, with only CSL's sub-1% dividend yield for company.

That contrasts painfully with prior years when CSL shareholders enjoyed double-digit share price growth over 2017, 2018, and 2019.

Not that the recent share price woes are entirely CSL's fault. It was trading at what was arguably quite a high price-to-earnings (P/E) ratio prior to the COVID-induced crash of 2020. Even today, it commands a solid P/E ratio of more than 36. And the pandemic has hit CSL hard, disrupting its plasma collection businesses around the world.

What's notable is that CSL has been markedly higher in the past. The company hit more than $336 a share back in early 2020, its current all-time high. And the company's present 52-week high is at $319.78.

Is 2022 the CSL share price's $300 year?

So is 2022 the year that CSL crosses the Rubicon and heads back to a share price north of $300?

Well, one broker who thinks it might be CSL's $300 year is Citi. As we covered yesterday, Citi has just retained its buy rating on CSL shares, replete with a 12-month share price target of $335. That would imply a potential upside of almost 25% on today's pricing.

Citi reckons CSL's plasma collections will come roaring back this year, exceeding pre-pandemic levels. This, the broker expects, will result in a "big boost to investor sentiment".

No doubt shareholders who have been waiting since November 2019 for the CSL share price to keep climbing will be hoping Citi's predictions are spot on. But we shall have to wait and see, as always.

At the current CSL share price, this ASX 200 healthcare giant has a market capitalisation of $129.6 billion, with a mostly unfranked dividend yield of 0.96%

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »